This is the second consecutive time Bidiphar has been in this top, affirming its position in the group of leading enterprises in the pharmaceutical and financial sectors that excel in the Vietnamese stock market.
Previously, in 2024, Bidiphar was honored for the first time in this list. In 2024, the Company achieved a revenue growth of 5% compared to the same period in 2023, equivalent to 1,817 billion VND; profit achieved a growth of 2% compared to the previous year, equivalent to 325 billion VND.
In 2025, the unit aims to increase its charter capital to VND 1,134 billion, revenue to VND 2,000 billion and pre-tax profit to VND 335 billion.
Bidiphar General Director Pham Thi Thanh Huong said that 2025 is an important pivotal year for Bidiphar's 5-year strategy 2025-2030. The unit continues to invest in research and development, focusing on high-tech products, especially cancer treatment drugs and other specialty drugs. This is a field in which Bidiphar has many years of experience and is highly appreciated by the market for its quality.
At the same time, we are promoting the strategy of expanding export markets in Southeast Asian and African countries and are promoting procedures to bring products to the European market, which has the strictest quality standards.
Source: https://baogialai.com.vn/bidiphar-tiep-tuc-duoc-vinh-danh-top-50-cong-ty-niem-yet-tot-nhat-viet-nam-post330640.html
Comment (0)